IMMX - NASDAQ

Immix Biopharma, Inc.

IMMX·NASDAQ

$8.63

+3.2%

HealthcareBiotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$469.57M

EPS-0.8900

P/E Ratio-9.70

Earnings Date08/14/2026

-23.93M

Operating Cash Flow

64%

3Y+223.0%

5Y+5813.0%

10Y+2929.0%

-7.21M

Investing Cash Flow

513%

3Y-

5Y-

10Y+98611.0%

107.39M

Financing Cash Flow

573%

3Y+3223.0%

5Y-

10Y+10127.0%

Immix Biopharma, Inc. Cash Conversion Engine

IMMX · NASDAQ

FCF Components

Net Income-29.44M

Depreciation & Amortization364.50K

Stock-Based Compensation2.44M

Change in Working Capital2.70M

Others0.00

Capital Expenditures-732.92K

Free Cash Flow-24.66M

Cash Flow Quality Analysis

FCF Conversion Rate

83.8%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

-3.1%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-56.4%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$2.70M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Immix Biopharma, Inc. Cash Flow Statement

IMMX • NASDAQ

Immix Biopharma, Inc. Cash Flow Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
OPERATING ACTIVITIES
Net Income	-29.4M	-21.6M	-15.6M	-8.2M	-24.4M	-1.1M	-972.8K
Depreciation & Amortization	364.5K	115.4K	5.5K	2.1K	2.5K	2.3K	1.1K
Stock-Based Compensation	2.4M	0.0	2.6M	624.1K	219K	0.0	0.0
Other Non-Cash Items	0.0	2.9M	0.0	0.0	23M	575K	0.0
Cash Taxes Paid	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(17.5K)	(20.6K)
Change in Working Capital	2.7M	4M	1.7M	195.2K	-391K	165.8K	181.7K
Cash from Operating Activities	-23.9M	-14.6M	-11.4M	-7.4M	-1.6M	-404.7K	-790K
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-732.9K	-1.2M	-52.1K	(0.0)	-802.0	(0.0)	-7.3K
Purchase of Investments	-6.5M	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Cash from Investing Activities	-7.2M	-1.2M	-52.1K	(0.0)	-802.0	(0.0)	-7.3K
FINANCING ACTIVITIES
Net Issuance of Common Stock	107.4M	15.9M	15.7M	3.3M	18.6M	0.0	0.0
Net Issuance of Debt	0.0	0.0	0.0	-50K	200K	0.0	1.1M
Share Repurchases	(0.0)	(0.0)	(0.0)	-100K	(0.0)	(0.0)	(0.0)
Other Financing Items	0.0	0.0	-232K	-6.7K	0.0	0.0	0.0
Cash from Financing Activities	107.4M	15.9M	15.5M	3.2M	18.8M	0.0	1.1M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates	3.8K	-3.6K	33.1K	-31.5K	-5.4K	61.8K	19K
Net Change in Cash	76.2M	172.2K	4.1M	-4.2M	17.3M	-342.9K	271.7K
Cash at Beginning of Period	17.7M	17.5M	13.4M	17.6M	391.1K	734K	462.3K
Cash at End of Period	93.9M	17.7M	17.5M	13.4M	17.6M	391.1K	734K
Free Cash Flow	-24.7M	-15.8M	-11.4M	-7.4M	-1.6M	-404.7K	-797.3K

SEC Filings

IMMX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 22, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 06, 2026	April 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 30, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	March 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
S-3 S-3 N/A	January 09, 2026	January 09, 2026		View Filing

Showing 1 to 10 of 67 filings

Related Guides

Blog Categories

Continue your IMMX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.